Literature DB >> 7862910

Differential regulation of the behavioral effects of chlordiazepoxide.

J S Shumsky1, I Lucki.   

Abstract

Chronic administration of the benzodiazepine (BZ) receptor agonist chlordiazepoxide (CDP) produced tolerance to its motor-impairing effects but little or no tolerance to its hypothermic effects or to its amnesic effects in the radial arm maze. Male Sprague-Dawley rats were pretreated for 14 days with CDP (25 mg/kg, b.i.d., IP) or saline, and chronic treatment was maintained throughout the experiments. Tolerance was evaluated by constructing dose-response curves to CDP following chronic administration of either CDP or saline. Tolerance developed to only certain behavioral effects of CDP. Tolerance developed to the motor-impairing effects of CDP as assessed in three different procedures: rotarod, spontaneous locomotor activity, and acquisition of the step-through inhibitory avoidance response. In contrast, tolerance did not develop to the hypothermic effects of CDP. Tolerance to the amnesic effects of CDP was contingent upon the behavioral procedure. For example, tolerance developed to reductions of retention latency in the step-through inhibitory avoidance response, but not to impairment of the acquisition of radial arm maze performance. These results are consistent with the effects of chronic BZ administration in humans and demonstrate a parallel regulation of drug effects, potentially mediated by regional differences in BZ receptor subtype regulation or composition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862910     DOI: 10.1007/bf02244749

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Tolerance development with chlordiazepoxide in relation to the plasma levels of the parent compound and its main metabolites in mice.

Authors:  J D Christensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

2.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

3.  A comparative study of certain pharmacologic responses following acute and chronic administrations of chlordiazepoxide.

Authors:  M E Goldberg; A A Manian; D H Efron
Journal:  Life Sci       Date:  1967-03-01       Impact factor: 5.037

4.  Benzodiazepines, but not antidepressants or neuroleptics, induce dose-dependent development of tolerance to lorazepam in psychiatric patients.

Authors:  K Aranko; M J Mattila; A Nuutila; J Pellinen
Journal:  Acta Psychiatr Scand       Date:  1985-11       Impact factor: 6.392

5.  Food preference following acute or chronic chlordiazepoxide administration: tolerance to an antineophobic action.

Authors:  S J Cooper; G Burnett; K Brown
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function.

Authors:  L G Miller; D J Greenblatt; J G Barnhill; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

7.  Differential effects of Ro15-1788 in actions of chlordiazepoxide and ethanol.

Authors:  A W Chan; M C Langan; D L Schanley; M L Penetrante; F W Leong; L Aldrich-Castanik
Journal:  Pharmacol Biochem Behav       Date:  1988-02       Impact factor: 3.533

8.  Long-term diazepam therapy and clinical outcome.

Authors:  K Rickels; W G Case; R W Downing; A Winokur
Journal:  JAMA       Date:  1983-08-12       Impact factor: 56.272

9.  Regional specificity of benzodiazepine receptor down-regulation during chronic treatment of rats with flurazepam.

Authors:  H C Rosenberg; T H Chiu
Journal:  Neurosci Lett       Date:  1981-06-12       Impact factor: 3.046

10.  Chronic use of benzodiazepines and psychomotor and cognitive test performance.

Authors:  I Lucki; K Rickels; A M Geller
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.